chrisvoncsefalvay/vaers-outcomes huggingface dataset:
My fathers death after he got it; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A male patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DEATH (death, medically significant), outcome "fatal", described as "My fathers death after he got it". The date and cause of death for the patient were unknown. It was not reported if an autopsy was performed. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Reported Cause(s) of Death: death
Received vaccine at 1:45pm. States at 9pm nausea, headache, fainted. Seen at Urgent Care given IV fluids for dehydration on 1/23/10. She and neighbor with similar symptoms.
he developed increased swelling; he developed increased swelling; stiffness in the extremity; he had increased bruising; he had increased bruising; began experiencing mild bruising; Initial information received on 13-Oct-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 52 years old male patient who experienced stiffness in the extremity, developed increased swelling, had mild bruising and increased bruising after receiving vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On 05-Oct-2022, the patient received a  dose of suspect INFLUENZA QUADRIVAL A-B VACCINE, Suspension for injection (dose, strength, expiry date: unknown) lot UT7741MA via intramuscular route in the left deltoid for prophylactic vaccination.  He went diving on 10-Oct and began experiencing mild bruising (contusion) (latency: 5 days). 11-Oct he had increased bruising (contusion, condition aggravated) and stiffness in the extremity(musculoskeletal stiffness) (latency: 6 days). 12-Oct the symptoms improved then he developed increased swelling  (swelling, condition aggravated)  (latency: 7 days). 13-Oct the swelling persisted but improved throughout the day and he reports is nearly fulkly resolved of all symptoms.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events.  At time of reporting, the outcome was Recovered / Resolved on 13-Oct-2022 for all events.
eating out a lot; Swelling in legs and feet; This is a spontaneous report from a contactable consumer (patient) received from a Pfizer-sponsored program. A 74-year-old male patient received his first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number and expiration date not reported), via an unspecified route of administration on 05May2021 (at an unspecified age) at 1st dose, single dose for COVID-19 immunization. Medical history included diabetes, blood pressure high, kidney transplant patient, allergic reactions, hay fever, sinusitis, and beginning stage of leukoma. Concomitant medications included empagliflozin (JARDIANCE) for diabetes, and unspecified 18 to 27 medications. The patient previously took diphenhydramine HCl (BENADRYL) for allergic reactions. The patient received his first dose on 05May2021 and was scheduled to receive the second dose on 26May2021, however, he reported that he received his second dose a day earlier than he was scheduled. The patient got confused since he thought that today was Wednesday, 26May2021, so he panicked and received his second dose today, 25May2021. The patient walked in panic at the vaccination site because he thought that it was closed down. The patient did not realize that he was a day early until after the injection was already given. The patient reported that on 16May2021, he had swelling in legs and feet but thinks that it was from one of his medical conditions. The patient stated that the swelling in his feet has been going on for about a week and he does not think that it has anything to do with the vaccine, and that maybe he ate too much salt. The patient further clarified that he probably ate too much salt as he was eating out a lot, and the salt from that might have added to the swelling. The patient was thinking if he could get some diuretic medication for this. The patient did not receive treatment for the event swelling in legs and feet. The patient did not go to the doctor for the swelling in legs and feet. Outcome of the events was unknown.   Information on the lot/batch number has been requested.; Sender's Comments: The event peripheral swelling is considered not related to BNT162B2, but intercurrent medical condition.
sneezing; This spontaneous case was reported by a consumer and describes the occurrence of SNEEZING (sneezing) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Mar-2021, the patient experienced SNEEZING (sneezing). At the time of the report, SNEEZING (sneezing) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Severe systemic muscle aches, low grade fever, headache, fatigue for over 24 hours. Pregnant at time of vaccination, 33 weeks, estimated day of delivery 11/29/21.
Information has been received from a 76 year old female who on 06-JUL-2010 was vaccinated with ZOSTAVAX (Merck) (Lot # unknown). The patient stated that on 06-JUL-2010, a few hours after receiving ZOSTAVAX (Merck) she started feeling body pains, dizziness, headache and difficulty walking. The patient sought unspecified medical attention. At the time of this report, the patient was recovering. Follow up information has been received which reported that on 06-JUL-2010, at 10:55, the 76 year old female patient was vaccinated with the first dose of ZOSTAVAX (Merck) (Lot # 665514/0145Z) into the left deltoid. It was reported that the patient never reported reactions. Follow up information has been received from the consumer who stated that she did not feel that her symptoms were related to ZOSTAVAX (Merck). She had had these type of symptoms for years. Additional information is not expected.
Extreme fatigue; This is a spontaneous report from a contactable consumer or other non hcp (patient herself). A 39-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EL3247, expiration date not reported), via an unspecified route of administration, administered in the left arm on 08Mar2021 12:00 (at the age of 39-years-old), as first dose, single dose for COVID-19 immunisation. Patient had no pertinent medical history and no concomitant medications. The patient was not pregnant at the time of vaccination. Patient has no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19; and since the vaccination, has not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. The patient experienced extreme fatigue on 09Mar2021 05:00. No treatment was received as a result of the event. Patient did not seek consult to physician or urgent care. The outcome of event was recovering.   No follow-up attempts are possible. No further information is expected.
The evening after receiving the shot, my arm was tender like it had been punched. The evening after receiving the shot, I had a rash on my neck and arms that was itchy and I had hives on my face and back.  These subsided after the evening, the itchiness stayed till next day, but then subsided. My arms started to feel bobbly and tender, lots of little bumps under the surface. Around 1/5 I noticed it was red, it started to itch a lot and then it became very firm/solid lump with swelling, and it was very red.  Swelling and solidness has subsided now, but redness is still there, however it's subsiding.
20 min p/receiving vax pt had wheezing & swollen eyes requiring Epi shot, breathing treatment, & DPH;
This spontaneous report as received from a nurse refers to an unspecified number of patients of unknown demographics. The patient's current conditions or medical history were not reported. On an unknown date, between January-February 2014, the patients were vaccinated with 17 doses (unspecified) of RECOMBIVAX HB (dose and route were not reported) lot's: H017304 expiry 11-JUL-2015; H020604 expiry 10-FEB-2015, that had been stored in January 2014 (starting 16-JAN-2014) at 30 F minimum for a total of 112 hours. No adverse effect reported. This is one of several reports from the same source. 1403USA000542, 1403USA001589, 1403USA001586, 1403USA011587. Additional information has been requested.
1/15/21 Tingling in lips, fingers and arms 1/16/21 Right sided facial numbness
Client called this am and states she started having pain in her leg yesterday. Pain is located behind her Right knee.  Referred her to call her doctor.
hot to the touch at the injection site; Redness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (hot to the touch at the injection site) and VACCINATION SITE ERYTHEMA (Redness at the injection site) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced VACCINATION SITE WARMTH (hot to the touch at the injection site) and VACCINATION SITE ERYTHEMA (Redness at the injection site). At the time of the report, VACCINATION SITE WARMTH (hot to the touch at the injection site) and VACCINATION SITE ERYTHEMA (Redness at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided. The patient used ice compress as treatment for the symptoms.
Bell palsy; This is a spontaneous report from a Pfizer- sponsored program. A contactable consumer (patient) reported that a male patient of an unspecified age received the first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date as a single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. After getting first vaccine, the patient got bell palsy on an unspecified date. The outcome of the event was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Patient had urticaria that presented as a diffuse rash over the course of 3 days and successfully treated with benedryl.  2/2/09 Received D/C summary for 10/29-10/31/2008. FINAL DX: urticarial rash. Records reveal rash had markedly improved w/tx by antihistamine by d/c to home.   1/27/09 Received hospital medical records of 10/29-10/31/2008. FINAL DX: no d/c summary available.  Allergy consult states likely infectious vs delayed reaction to vaccine. Records reveal patient experienced erythematous maculopapular rash all over x 1 day, irritability, reduced oral intake x 2 days & loose green stool.  Exam revealed erythematous swelling of all extremities thought to be coaslescing welts & temp 38.3..  Tx w/antibiotics & antihistamins.  LP done.  Allergy consult done & referred for additional allergy testing prior to further vaccines.  1/12/09 Received PCP medical records & vaccine records which included RO given 10/24/08. FINAL DX: H&P states allergic type rash Records reveal patient experienced congestion as reported by parent on 10/24 but MD exam was WNL.  RTC w/erythematous rash & extremity edema x 1 day on 10/29.  Sent to hospital for eval.  D/C from hospital 10/31 where dx w/urticaria.  Seen by Allergist 11/18, initial allergy tests were neg.  RTC for additional allergy testing 12/30 & had URI at that time w/nasal congestion & no fever.  Allergy tesing neg.  Not tested for RO & asked to hold until tested.
itching on his back, chest,stomach, legs and back of his neck; full blown red spots on his chest; This case was reported by a consumer via call center representative and described the occurrence of pruritus in a 61-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of pruritus (for tolerance of 1st dose refer case US2020023462).   On 26th December 2019, the patient received the 2nd dose of Shingrix. On 27th December 2019, 1 days after receiving Shingrix, the patient experienced pruritus and red rash. The patient was treated with topical steroid nos (Steroid Cream). Rechallenge with Shingrix was positive. On an unknown date, the outcome of the pruritus and red rash were unknown.   The reporter considered the pruritus to be related to Shingrix. It was unknown if the reporter considered the red rash to be related to Shingrix.  Additional details were provided as follows: The patient did not had any allergy history. The day after vaccination the patient had a full blown red spots on his chest and back.  The patient had severe itching on his back, chest,stomach, legs and back of his neck but not his face.    The patient underwent blood work but nothing was found from that.  The patient was prescribed a bandaid fix steroid cream that resolved the issue, but it returned. The patient also saw dermatologist but no resolution. The patient had itching 2 months after the vaccination.      Lab Comments: Laboratory test performed on an unknown date
Info has been received from a physician concerning a 40 year old female physician with ragweed allergy who on 7/26/04 was vaccinated with a pediatric dose of hepatitis A virus vaccine inactivated (0.5ml), IM. Concomitant therapy included Allegra. Subsequently, the pt developed a sore shoulder. The pt recovered. Additional info has been requested.
Bell's Palsy; A spontaneous report was received from a consumer concerning an 82-year-old, female patient who received  Moderna's  Covid-19 vaccine (mRNA1273) and developed Bell's palsy and experienced pain and burning in eyes and a severe headache. . The patient's medical history includes heart disease. Products known to have been used by the patient, within two weeks prior to the event, included clopidogrel bisulfate.  The patient received first of two planned dose of mRNA-1273 (Batch Number 041L20A) intramuscularly on 14-JAN-2021 for prophylaxis of Covid-19 infection.  On 18-FEB-2021, it was reported that the patient had eye pain and some symptoms of Bell's Palsy. On 19-FEB-2021, the symptoms worsened and so on 20-FEB-2021, the patient was taken to urgent care where she was diagnosed with Bell's palsy. The left side of the patient's face, according to her husband, was drooping and she was having trouble eating and drinking. The patient also had a severe headache.   Treatment for the event included prednisone. Patient was also wearing a patch to help prevent pain.   Action taken with mRNA-1273 in response to the events was not provided.  The outcome of the events, Bell's palsy  was considered unknown.; Reporter's Comments: Very limited information regarding the events has been provided at this time.  Further information has been requested.
started with herpes virus in "below" area two days ago; Interchange of vaccine products; This spontaneous case was reported by a consumer and describes the occurrence of HERPES VIRUS INFECTION (started with herpes virus in "below" area two days ago) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for COVID-19 vaccination: Pfizer (given in left non-dominant arm. Lot number: Unknown) on 22-Mar-2021 and Pfizer (given in left non-dominant arm. Lot number: Unknown) on 12-Apr-2021. Past adverse reactions to the above products included No adverse event with Pfizer and Pfizer.    On 16-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Nov-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). On 18-Nov-2021, the patient experienced HERPES VIRUS INFECTION (started with herpes virus in "below" area two days ago). On 16-Nov-2021, INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) had resolved. At the time of the report, HERPES VIRUS INFECTION (started with herpes virus in "below" area two days ago) had not resolved.            No concomitant medication were given.  Treatment include Little bit of cream
Tightening of throat (thickening) some itch.; Minor difficulty swallowing; This is a spontaneous report from a contactable consumer (patient). A 73-years-old female patient received first dose of bnt162b2 (Solution injection; Batch/Lot number was not reported), via an unspecified route of administration, administered in Arm Left on 01Mar2021 11:00 as single dose (at the age of 73-years-old) for covid-19 immunisation. Medical history included breast cancer, coronary artery, hypertension, hypothyroidism. Patient has known allergies which included anaphylactic history to fin fish. Concomitant medications included levothyroxine sodium, lisinopril, atorvastatin and vitamin D. The patient experienced tightening of throat (thickening) some itch and minor difficulty swallowing on 01Mar2021 12:00. AE resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care. Therapeutic measures were not taken in response to the events. Patient did not take any other vaccine in 4 weeks. Patient did not have covid prior to vaccination. Patient was not tested for covid post vaccination. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained
patient started losing sight and hearing and starting sweating.  ems was called and patient was helped to the floor because he said he was feeling faint.  Before ems arrived he was feeling much better.  EMS checked him out (blood pressure and blood sugar).  Patient remained for another 30 minutes before saying he was ok to go home.
Day 1&2: Aches,slight fever, headache Day 3:  breast tenderness, followed by lymph node under right arm swelling/very painful (12 hours after tenderness began)                  face swelling under eyes, hand swelling and hand joint pain Days 3/4/5: joint pain spreading throughout body.  Some sharp pains in various joints Day 5/6: migraine again, not as severe (responded to my medicine better)  day 6 migraine better (didn't take medicine)(zololatriptan)                     Sharp pain in my lower right side (like the ovarian cyst pain I had when I was ovulating)
Patient experienced nausea and vomiting 10 to 15 minutes after injection, which lasted approximately 20 to 30 minutes. No nausea, vomiting or diarrhea prior to immunization.
Two hours post vax, pt crying, leg swollen and red with a lump and fever. Pt cried for 2 hours.
Less than 24 hours of the vaccination I started experiencing cold sweats, felt lethargic. After walking I I felt muscle aches, as the day progressed I began experiencing severe joint pain. Started near injection site and then traveled into my shoulders and up into my neck, I started running a fever and then pain keeps intensifying now in my legs. I feel chest wall tightness muscular in nature. Pain 9/10.
8/23/12 DIARRHEA 8/24/12 RASH ON FACE  8/25/12 RASH AT INJECTION SITE 8/26/12 LETHARGY 8/27/12 HIGH TEMPERATURE, FEVER ABOVE 100.5
Employee complained of redness, swelling, warmth and discomfort around injection site.  Area red, warm to touch and uncomfortable to touch on exam.
Advised by the local authority that Pfizer Covid Vaccine adminstered was stable based on Manufacturer but was not stored based on EUA guidelines and deemed not viable.  Reached out to the patients effected via phone and sent the required letter to offer revaccination.  13 Patients were effected by this.
Patient here today for Right thigh red area after shot on Friday, an on Left has softball size red rash where the immunizations were. Patient did not have shots at Medical Clinic. Mom not sure which shots were given where, patient had VARIVAX, MMR, Polio, and DTap. BENADRYL PRN and Ibuprofen PRN
PROQUAD underwent a temperature excursion and was administered; This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and gender. On 11-JUN-2021, the patient was vaccinated with a dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (lot # T036562 exp date 26-APR-2022) rHA (dose and route not reported) that underwent a temperature excursion. Previous temperature of excursion was 6°F to 14°F (14F) for 2 hours, 14°F to 46°F (45.5F) 1 hour and 30 minutes and 6°F t o14°F (14.4F) for 2 hours.  This is one of several reports received from the same source. ; Sender's Comments:  US-009507513-2106USA006475: US-009507513-2106USA006476: US-009507513-2106USA006477: US-009507513-2106USA006478: US-009507513-2106USA006479: US-009507513-2106USA006480: US-009507513-2106USA006481: US-009507513-2106USA006482: US-009507513-2106USA006483: US-009507513-2106USA006484: US-009507513-2106USA006485: US-009507513-2106USA006486: US-009507513-2106USA006487: US-009507513-2106USA006488: US-009507513-2106USA006064: US-009507513-2106USA006490: US-009507513-2106USA006491: US-009507513-2106USA006492: US-009507513-2106USA006493: US-009507513-2106USA006494: US-009507513-2106USA006495: US-009507513-2106USA006496: US-009507513-2106USA006497: US-009507513-2106USA006498: US-009507513-2106USA006458: US-009507513-2106USA006459: US-009507513-2106USA006460: US-009507513-2106USA006461: US-009507513-2106USA006462: US-009507513-2106USA006463: US-009507513-2106USA006464: US-009507513-2106USA006465: US-009507513-2106USA006466: US-009507513-2106USA006467: US-009507513-2106USA006468: US-009507513-2106USA006469: US-009507513-2106USA006470: US-009507513-2106USA006471: US-009507513-2106USA006472: US-009507513-2106USA006473: US-009507513-2106USA006474:
Covid rebound after taking paxlovid; Covid rebound after taking paxlovid; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 42-year-old female patient (not pregnant) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown), in right arm for covid-19 immunisation. The patient's relevant medical history included: "Diabetes type 2" (unspecified if ongoing), notes: Other medical history: Diabetes type 2. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "Covid rebound after taking paxlovid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Headache, fever 100.2, nausea & arm tenderness.  Took Advil.